Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RHA 4 + lidocaine is an **injectable dermal filler** composed of **cross-linked hyaluronic acid** combined with **lidocaine** as a local anesthetic[2][3][4][5][7]. Its primary use is for the **correction of moderate to severe dynamic facial wrinkles and folds**, such as nasolabial folds, cheek augmentation, and restoration of facial volume in adults. The hyaluronic acid in RHA 4 is both modified and non-modified to mimic the behavior and elasticity of native hyaluronic acid found in the skin, improving volume while maintaining natural movement and softness. Lidocaine is included to reduce discomfort during injection. The filler is biodegradable and is administered into the deep dermis or superficial subcutaneous tissue. **Teoxane** developed and manufactures this product, often in collaboration or distribution partnership with companies like **Revance** for the U.S. market[2][3][6][7]. The product is FDA approved for specific aesthetic indications in adults[7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on RHA 4 + lidocaine.